The current program relies heavily on the ability to produce recombinant monoclonal antibodies by transient transfection. Drs. Steinman and Ravetch will make use of such reagents in targeting DC subsets in vivo and in producing modified antibodies that are capable of DC targeting and activation. Because they will be used in vivo and in tissue culture experiments uniform quality control for these reagents including LPS testing will be critical. Dr. Nussenzweig will produce hundreds of different human monoclonal antibodies by the same transfection method in his part ofthe program for testing in HIV binding and neutralization assays. These assays will require hundreds of micrograms of the antibody reagents. The proposed core will produce recombinant antibodies for all ofthe participants in the program and in addition store and distribute the reagents to collaborators and to the scientific community

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI081677-05
Application #
8523756
Study Section
Special Emphasis Panel (ZAI1-KS-I)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2013
Total Cost
$203,688
Indirect Cost
$79,811
Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Pantel, Austin; Teixeira, Angela; Haddad, Elias et al. (2014) Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol 12:e1001759
DiLillo, David J; Tan, Gene S; Palese, Peter et al. (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc?R interactions for protection against influenza virus in vivo. Nat Med 20:143-51
Halper-Stromberg, Ariel; Lu, Ching-Lan; Klein, Florian et al. (2014) Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:989-99
Bournazos, Stylianos; Klein, Florian; Pietzsch, John et al. (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158:1243-53
Anandasabapathy, Niroshana; Feder, Rachel; Mollah, Shamim et al. (2014) Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. J Exp Med 211:1875-91
Mollah, Shamim A; Dobrin, Joseph S; Feder, Rachel E et al. (2014) Flt3L dependence helps define an uncharacterized subset of murine cutaneous dendritic cells. J Invest Dermatol 134:1265-75
Gruell, Henning; Bournazos, Stylianos; Ravetch, Jeffrey V et al. (2013) Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol 87:8535-44
Gaebler, Christian; Gruell, Henning; Velinzon, Klara et al. (2013) Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160ýýc(BaL.). J Immunol Methods 397:47-54
Klein, Florian; Diskin, Ron; Scheid, Johannes F et al. (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153:126-38
Mouquet, Hugo; Warncke, Malte; Scheid, Johannes F et al. (2012) Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A 109:875-80

Showing the most recent 10 out of 17 publications